Collaboration to Advance Hematology Diagnostics

By HospiMedica staff writers
Posted on 04 Feb 2004
An alliance to develop new, clinically important hematology diagnostics has been announced by Bio-Reference Laboratories, Inc. (Elmwood Park, NJ, USA) and Sysmex America, Inc. (Mundelein, IL, USA).

Bio-Reference is a large, independent regional clinical laboratory in the northeastern U.S. with a specialized cancer pathology and molecular diagnostics unit called GenPath. Sysmex is a leading diagnostic instrument manufacturer and information systems developer. Bio-Reference believes that Sysmex's innovation and technical superiority can help the company identify and validate new hematology diagnostics. Sysmex was the first company to develop an approved automated measurement of immature granulocytes, the first to automate nucleated red blood cells, using fluorescent flow cytometry, and the first to bring the diode laser to hematology.

"Sysmex America's innovation and technical superiority have resulted in a ‘best of breed' philosophy that has produced a hematology product offering known for its high quality and the introduction of clinically important new parameters,” said Marc D. Grodman, M.D., president and CEO of Bio-Reference Labs. "This is the type of partner that Bio-Reference Laboratories seeks in order to provide its physician-customers with competitive, world-class diagnostics.”




Related Links:
Bio-Reference
Sysmex

Latest Business News